Streetbeat News

Price Targets

AVDX

Wells Fargo analyst Andrew Bauch maintains an Equal-Weight rating on AvidXchange Holdings (NASDAQ:AVDX) and raises the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:52 pm

AFRM

Wells Fargo analyst Andrew Bauch maintains an Equal-Weight rating on Affirm Holdings (NASDAQ:AFRM) and raises the price target from $17 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:51 pm

FATE

Wedbush analyst David Nierengarten has maintained a Neutral rating on Fate Therapeutics (NASDAQ:FATE) and lowered the price target from $6 to $3.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:50 pm

ELME

Wells Fargo analyst Blaine Heck has maintained an Equal-Weight rating on Elme Communities (NYSE:ELME) and lowered the price target from $15.5 to $14.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:48 pm

NXST

Wells Fargo analyst Steven Cahall has maintained an Equal-Weight rating on Nexstar Media Gr (NASDAQ:NXST) but lowered the price target from $175 to $167.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:46 pm

GTN

Wells Fargo analyst Steven Cahall has maintained an Underweight rating on Gray Television (NYSE:GTN) and lowered the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:46 pm

XENE

Wedbush analyst Laura Chico has maintained an 'Outperform' rating on Xenon Pharmaceuticals (NASDAQ:XENE) but lowered the price target from $47 to $46.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:45 pm

WBD

Wells Fargo analyst Steven Cahall has maintained an Overweight rating on Warner Bros. Discovery (NASDAQ:WBD) but lowered the price target from $20 to $16.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:45 pm

DIS

Wells Fargo analyst Steven Cahall has maintained an Overweight rating on Walt Disney (NYSE:DIS) and raised the price target from $110 to $115.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:43 pm

ACET

Wedbush analyst Robert Driscoll has maintained an 'Outperform' rating on Adicet Bio (NASDAQ:ACET) but lowered the price target from $17 to $5.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:43 pm